Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricMRKMerck & Co.AZNAstraZeneca PLCNVSNovartis AG
Snapshot
Price$151.96$168.45$141.41
Market cap$319.99B$284.73B$261.56B
Valuation
P/E41.9x25.9x19.6x
Forward P/E59.8x19.4x17.9x
Growth
Revenue growth2.9%9.9%5.8%
EPS growth-48.3%33.7%9.3%
Profitability
Net margin13.6%17.2%24.1%
ROE17.9%22.3%31.7%
Balance sheet & cash
Debt / equity0.94x0.61x0.77x
Free cash flow yield2.9%3.1%4.2%
Dividend yield3.0%1.7%2.9%
Verdict
Investment ratingWeak· 35Favorable· 62Favorable· 67

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearMRKtoday $152AZNtoday $168NVStoday $141
2027$116.25 – $170.50+12% CAGR$168.93 – $247.76+47% CAGR$115.89 – $169.97+20% CAGR
2028$118.57 – $173.91+7% CAGR$225.87 – $331.28+40% CAGR$126.63 – $185.73+15% CAGR
2029$120.95 – $177.39+5% CAGR$302.01 – $442.95+38% CAGR$138.37 – $202.94+13% CAGR
2030$123.36 – $180.94+4% CAGR$403.82 – $592.27+37% CAGR$151.20 – $221.76+12% CAGR
2031$125.83 – $184.55+4% CAGR$539.95 – $791.92+36% CAGR$165.21 – $242.31+11% CAGR
5-yr CAGR-3.7% – 4.0%26.2% – 36.3%3.2% – 11.4%